Clinical trial
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis
NCT00245622 · Opexa Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT00245622 |
|---|---|
| Title | Autologous T Cell Vaccine (TCV) for Multiple Sclerosis |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MS |
| Acronym | TERMS |
| Lead sponsor | Opexa Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Biological |
| Interventions | Tovaxin Autologous T cell vaccine, Placebo |
| Enrollment | 150 |
| Start date | May 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Oct 28, 2005 |
| Last update posted | Mar 10, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: